Progression-free patients were randomly assigned with an interactive voice-response system by block ( size four ) randomisation ( 1:1 ) to receive either bevacizumab and capecitabine or bevacizumab only ( bevacizumab 15 mg/kg on day 1 ; capecitabine 1000 mg/m ( 2 ) twice per day on days 1-14 , every 3 weeks ) until progression , stratified by oestrogen receptor status ( positive vs negative ) , visceral metastases ( present vs absent ) , response status ( stable disease vs response vs non-measurable ) , and lactate dehydrogenase concentration ( 15 vs > 15upper limit of normal ) .